 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 September 2001 | Volume 135 Issue 5 | Pages 322-327
Background: The factor V Leiden mutation is a common genetic defect associated with an increased risk for venous thromboembolism. The clinical implications for asymptomatic carriers of this mutation and, consequently, the usefulness of screening families in which a proband has both the mutation and venous thromboembolism are unclear.
Objective: To determine the incidence of venous thromboembolism in asymptomatic carriers of the factor V Leiden mutation.
Design: Prospective cohort study.
Setting: University hospitals in the Netherlands.
Participants: 470 asymptomatic carriers of the factor V Leiden mutation (234 men, 236 women; mean age, 43 years [range, 15 to 88 years]), 12 of whom were homozygous. Carriers were identified by screening the first-degree relatives (>15 years of age) of 247 symptomatic probands.
Measurements: Objectively diagnosed episodes of venous thromboembolism and the relationship between incidence and exposure to high-risk situations.
Results: Nine venous thromboembolic events were observed in 1564 observation-years, resulting in an annual incidence of 0.58% (95% CI, 0.26% to 1.10%). The incidence of spontaneous venous thromboembolism was 0.26% (CI, 0.07% to 0.65%) per year; 3.5% (CI, 0.1% to 17.8%) per episode of surgery, trauma, or immobilization; 0.0% (CI, 0.0% to 19.5%) per pregnancy; 1.8% (CI, 0.4% to 5.2%) per year of oral contraceptive use; and 2.9% (CI, 0.8% to 15.3%) per year of use of hormone replacement therapy.
Conclusions: The absolute annual incidence of spontaneous venous thromboembolism in asymptomatic carriers of the factor V Leiden mutation is low and does not justify routine screening of the families of symptomatic patients.
Author and Article Information
From Academic Medical Center, Amsterdam; University Hospital Groningen, Groningen; and University Hospital of Maastricht, Maastricht, the Netherlands.
Grant Support: By the Zorg Onderzoek Nederland (grant 28-2783).
Requests for Single Reprints: Saskia Middeldorp, MD, Department of Vascular Medicine, Academic Medical Center F4-277, Box 22700, 1100 DE Amsterdam, the Netherlands.
Current Author Addresses: Drs. Middeldorp, Koopman, and Büller: Department of Vascular Medicine, Academic Medical Center F4-277, Box 22700, 1100 DE Amsterdam, the Netherlands.
Drs. Meinardi and van der Meer: Department of Hematology, Division of Hemostasis, Thrombosis and Rheology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Drs. van Pampus and Hamulyák: Department of Hematology, Academic Hospital Maastricht, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands.
Dr. Prins: Department of Clinical Epidemiology and Medical Technology Assessment, Academic Hospital Maastricht, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands.
Author Contributions: Conception and design: S. Middeldorp, M.M.W. Koopman, K. Hamulyák, J. van der Meer, M.H. Prins, H.R. Büller.
Analysis and interpretation of the data: S. Middeldorp, M.H. Prins, H.R. Büller.
Drafting of the article: S. Middeldorp, H.R. Büller.
Critical revision of the article for important intellectual content: J.R. Meinardi, M.M.W. Koopman, E.C.M. van Pampus, K. Hamulyák, J. van der Meer.
Final approval of the article: S. Middeldorp, J.R. Meinardi, M.M.W. Koopman, E.C.M. van Pampus, K. Hamulyák, J. van der Meer, M.H. Prins, H.R. Büller.
Provision of study materials or patients: S. Middeldorp, J.R. Meinardi, M.M.W. Koopman, E.C.M. van Pampus, K. Hamulyák, J. van der Meer.
Statistical expertise: S. Middeldorp, M.H. Prins.
Obtaining of funding: S. Middeldorp, H.R. Büller.
Administrative, technical, or logistic support: S. Middeldorp, E.C.M. van Pampus, K. Hamulyák, J. van der Meer, M.H. Prins.
Collection and assembly of data: S. Middeldorp, J.R. Meinardi, E.C.M. van Pampus, K. Hamulyák, J. van der Meer. ARTICLE
A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Coppens, M. H. van de Poel, I. Bank, K. Hamulyak, J. van der Meer, N. J. Veeger, M. H. Prins, H. R. Buller, and S. Middeldorp A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation Blood, October 15, 2006; 108(8): 2604 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Curb, R. L. Prentice, P. F. Bray, R. D. Langer, L. Van Horn, V. M. Barnabei, M. J. Bloch, M. G. Cyr, M. Gass, L. Lepine, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med, April 10, 2006; 166(7): 772 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dizon-Townson, C. Miller, B. Sibai, C. Y. Spong, E. Thom, G. Wendel Jr, K. Wenstrom, P. Samuels, M. A. Cotroneo, A. Moawad, et al. The Relationship of the Factor V Leiden Mutation and Pregnancy Outcomes for Mother and Fetus Obstet. Gynecol., September 1, 2005; 106(3): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cushman Inherited Risk Factors for Venous Thrombosis Hematology, January 1, 2005; 2005(1): 452 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cushman, L. H. Kuller, R. Prentice, R. J. Rodabough, B. M. Psaty, R. S. Stafford, S. Sidney, F. R. Rosendaal, and for the Women's Health Initiative Investigators Estrogen Plus Progestin and Risk of Venous Thrombosis JAMA, October 6, 2004; 292(13): 1573 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Wittkowsky Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 308 - 316. [Abstract] [PDF]
|
|
|
|
 |
|
 S. E. Humphries, P. M. Ridker, and P. J. Talmud Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 628 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit Thrombophilia and New Anticoagulant Drugs Hematology, January 1, 2004; 2004(1): 424 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Orwoll Risk for Venous Thromboembolism in Carriers of the Factor V Leiden Mutation Ann Intern Med, January 7, 2003; 138(1): 76 - 76. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Burke Genetic Testing N. Engl. J. Med., December 5, 2002; 347(23): 1867 - 1875. [Full Text] [PDF]
|
|
|
|
|
|
M. Procopiou Genetic Hypercoagulability Syndromes: Does Testing Really Matter? Arch Intern Med, August 12, 2002; 162(15): 1784 - 1785. [Full Text] [PDF]
|
|
|
|
 |
|
 H. V Joffe and S. Z Goldhaber Laboratory thrombophilias and venous thromboembolism Vascular Medicine, May 1, 2002; 7(2): 93 - 102. [Abstract] [PDF]
|
|
|
|
|
|
C. E. Ettingshausen, K. Kurnik, R. Schobess, W. D. Kreuz, S. Halimeh, H. Pollman, U. Nowak-Gottl ;, J. M. Journeycake, and G. R. Buchanan Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease Blood, February 15, 2002; 99(4): 1499 - 1499. [Full Text] [PDF]
|
|
|
|
 |
|
 Low Incidence of Thromboembolism in Asymptomatic Carriers of Factor V Leiden Journal Watch (General), September 21, 2001; 2001(921): 2 - 2. [Full Text]
|
|
Article
